>>> US Research Calls I

Research Calls I
  • Upgrades
    • Deere (DE) upgraded to Buy from Hold at Melius Research, tgt $750
    • Invitation Homes (INVH) upgraded to Buy from Neutral at Citi, tgt $35
    • MasTec (MTZ) upgraded to Buy from Neutral at Goldman Sachs, tgt $168
    • Ormat Technologies (ORA) upgraded to Overweight from Equal Weight at Barclays, tgt $86
    • Prudential plc (PUK) upgraded to Buy from Hold at Deutsche Bank
    • Sarepta (SRPT) upgraded to Outperform from Sector Perform at Scotiabank, tgt $80
    • Urban Outfitters (URBN) upgraded to Hold from Underperform at Jefferies, tgt $70
  • Downgrades
    • AMH (AMH) downgraded to Neutral from Buy at Citi, tgt $41
    • Brown-Forman (BF.B) downgraded to Neutral from Outperform at BNP Paribas Exane, tgt $28
    • CrowdStrike (CRWD) downgraded to Market Perform from Outperform at Bernstein, tgt $371
    • McDonald's (MCD) downgraded to Hold from Buy at Loop Capital, tgt $315
    • MYR Group (MYRG) downgraded to Neutral from Buy at Goldman Sachs, tgt $168
  • Others
    • American Integrity Insurance (AII) initiated with an Outperform at William Blair, tgt
    • Amneal Pharmaceuticals (AMRX) initiated with a Buy at Goldman Sachs, tgt $12
    • Atai Life Sciences (ATAI) initiated with a Buy at Lucid Capital, tgt $12
    • Chagee (CHA) initiated with an Outperform at CICC, tgt $41.50
    • Climb Bio (CLYM) initiated with an Outperform at Oppenheimer, tgt $10
    • Cybin (CYBN) initiated with a Buy at Lucid Capital, tgt $106
    • Hut 8 (HUT) initiated with a Buy at Roth Capital, tgt $25
    • QXO (QXO) initiated with an Outperform at Wolfe Research, tgt $44
    • Solaris Energy (SEI) initiated with an Overweight at Barclays, tgt $42
    • Senti Bio (SNTI) initiated with a Buy at Laidlaw, tgt $5
    • Solventum (SOLV) initiated with a Sector Weight at KeyBanc
    • Sweetgreen (SG) initiated with an Equal Weight at Barclays, tgt $16
    • Teva (TEVA) initiated with a Buy at Goldman Sachs, tgt $24
    • Teradata (TDC) resumed with Neutral from Sell at UBS, tgt $24
    • Viatris (VTRS) initiated with a Neutral at Goldman Sachs, tgt $10